Dr. Reddy's Laboratories Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Dr. Reddy's LaboratoriesDer Gewinn des Unternehmens wird voraussichtlich um 1% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 4.9% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich sinken um 1.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 14.8% betragen.
Wichtige Informationen
-1.0%
Wachstumsrate der Gewinne
-1.9%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 18.0% |
| Wachstumsrate der Einnahmen | 4.9% |
| Zukünftige Eigenkapitalrendite | 14.8% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 26 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Dr. Reddy's Laboratories Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next
Nov 08
Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
Aug 01Earnings Beat: Dr. Reddy's Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 02Recent updates
Are Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Investors Paying Above The Intrinsic Value?
Nov 23Dr. Reddy's Laboratories Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next
Nov 08Insufficient Growth At Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Hampers Share Price
Nov 01Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?
Oct 14If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Aug 19Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
Aug 01The Market Doesn't Like What It Sees From Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Earnings Yet
Jul 30Dr. Reddy's Laboratories (NSE:DRREDDY) Seems To Use Debt Rather Sparingly
Jul 12Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00
Jun 23Additional Considerations Required While Assessing Dr. Reddy's Laboratories' (NSE:DRREDDY) Strong Earnings
Jun 20Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Dividend Of ₹40.00
May 26Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00
May 10With EPS Growth And More, Dr. Reddy's Laboratories (NSE:DRREDDY) Makes An Interesting Case
May 06There Is A Reason Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Price Is Undemanding
Apr 18Earnings Beat: Dr. Reddy's Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 02Should You Be Adding Dr. Reddy's Laboratories (NSE:DRREDDY) To Your Watchlist Today?
Jan 19Why Investors Shouldn't Be Surprised By Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Low P/E
Jan 01Dr. Reddy's Laboratories (NSE:DRREDDY) Has A Rock Solid Balance Sheet
Oct 21If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Oct 03Dr. Reddy's Laboratories (NSE:DRREDDY) Could Easily Take On More Debt
Jul 14Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00
Jun 24Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Larger Dividend Than Last Year
Jun 10Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00
May 27Dr. Reddy's Laboratories' (NSE:DRREDDY) Dividend Will Be Increased To ₹40.00
May 13Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?
Apr 11If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Mar 06These 4 Measures Indicate That Dr. Reddy's Laboratories (NSE:DRREDDY) Is Using Debt Reasonably Well
Jan 10If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Dec 05Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2027 | 341,318 | 49,595 | 53,780 | 67,381 | 33 |
| 3/31/2026 | 346,573 | 61,438 | 51,533 | 67,263 | 37 |
| 3/31/2025 | 320,983 | 58,529 | 24,734 | 59,254 | 36 |
| 9/30/2024 | 299,867 | 53,332 | 8,830 | 34,069 | N/A |
| 6/30/2024 | 288,507 | 55,579 | 21,012 | 42,679 | N/A |
| 3/31/2024 | 279,164 | 55,684 | 18,019 | 45,433 | N/A |
| 12/31/2023 | 271,302 | 52,206 | 28,713 | 53,592 | N/A |
| 9/30/2023 | 266,854 | 50,888 | 49,179 | 72,115 | N/A |
| 6/30/2023 | 261,109 | 47,216 | 41,123 | 63,470 | N/A |
| 3/31/2023 | 245,879 | 45,067 | 40,009 | 58,875 | N/A |
| 12/31/2022 | 237,279 | 36,350 | 29,170 | 48,315 | N/A |
| 9/30/2022 | 222,776 | 30,944 | 21,866 | 42,386 | N/A |
| 6/30/2022 | 217,351 | 29,736 | 16,755 | 38,211 | N/A |
| 3/31/2022 | 214,391 | 23,568 | 12,005 | 28,108 | N/A |
| 12/31/2021 | 207,307 | 26,317 | 14,976 | 30,255 | N/A |
| 9/30/2021 | 203,406 | 19,450 | 1,597 | 17,194 | N/A |
| 6/30/2021 | 194,741 | 17,153 | 7,335 | 21,342 | N/A |
| 3/31/2021 | 189,722 | 17,238 | 23,142 | 35,703 | N/A |
| 12/31/2020 | 186,756 | 21,256 | 15,528 | 26,983 | N/A |
| 9/30/2020 | 181,298 | 15,361 | 22,026 | 30,069 | N/A |
| 6/30/2020 | 180,340 | 18,663 | 24,354 | 30,921 | N/A |
| 3/31/2020 | 174,600 | 19,498 | 23,985 | 29,841 | N/A |
| 12/31/2019 | 170,448 | 16,200 | 28,930 | 34,006 | N/A |
| 9/30/2019 | 165,110 | 26,749 | 37,511 | 42,937 | N/A |
| 6/30/2019 | 155,079 | 20,862 | 37,400 | 43,559 | N/A |
| 3/31/2019 | 153,851 | 18,795 | 21,213 | 28,704 | N/A |
| 12/31/2018 | 149,034 | 17,473 | 19,953 | 27,774 | N/A |
| 9/30/2018 | 148,594 | 15,965 | 9,576 | 19,007 | N/A |
| 6/30/2018 | 145,903 | 13,776 | N/A | 14,986 | N/A |
| 3/31/2018 | 141,855 | 9,806 | N/A | 18,029 | N/A |
| 12/31/2017 | 141,827 | 9,909 | N/A | 20,765 | N/A |
| 9/30/2017 | 140,588 | 11,266 | N/A | 18,478 | N/A |
| 6/30/2017 | 140,907 | 11,367 | N/A | 14,480 | N/A |
| 3/31/2017 | 139,870 | 12,039 | N/A | 21,513 | N/A |
| 12/31/2016 | 141,269 | 9,660 | N/A | 22,252 | N/A |
| 9/30/2016 | 144,127 | 10,751 | N/A | 29,018 | N/A |
| 6/30/2016 | 148,410 | 15,019 | N/A | 37,693 | N/A |
| 3/31/2016 | 153,866 | 20,013 | N/A | 41,247 | N/A |
| 12/31/2015 | 155,850 | 24,456 | N/A | 42,252 | N/A |
| 9/30/2015 | 154,602 | 24,409 | N/A | 36,012 | N/A |
| 6/30/2015 | 150,592 | 22,932 | N/A | 29,083 | N/A |
| 3/31/2015 | 147,360 | 22,179 | N/A | 25,033 | N/A |
| 12/31/2014 | 143,474 | 21,806 | N/A | 22,860 | N/A |
| 9/30/2014 | 140,380 | 22,247 | N/A | 23,151 | N/A |
| 6/30/2014 | 138,076 | 23,409 | N/A | 19,532 | N/A |
| 3/31/2014 | 132,170 | 21,515 | N/A | 19,463 | N/A |
| 12/31/2013 | 130,043 | 22,409 | N/A | 13,951 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: DRREDDYFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-1% pro Jahr).
Ertrag vs. Markt: DRREDDYFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-1% pro Jahr).
Hohe Wachstumserträge: DRREDDYFür die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.
Einnahmen vs. Markt: DRREDDYDie Einnahmen des Unternehmens (4.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (10.5% pro Jahr).
Hohe Wachstumseinnahmen: DRREDDYDie Einnahmen des Unternehmens (4.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: DRREDDYDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (14.8%).